Wegovy is given through a pen injection, under the skin weekly, and begins with a25 mg dose, per week for the initial four weeks before gradually increasing every four weeks until it reaches a goal of 2.4 mg per week as the maximum dosage
It addresses the entire abdomen, from the rib cage to the pubic bone
Primary risks include additive cardiovascular effects (increased heart rate and blood pressure), intensified gastrointestinal symptoms (nausea, vomiting, diarrhea), and potential for serious adverse events including pancreatitis and acute kidney injury requiring close monitoring
Rossing P, Baeres FMM, Bakris G et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
We aimed to provide a comprehensive overview of the existing research on the therapeutic effects and underlying molecular mechanisms of TCM and TM, encompassing herbal formulations, single botanical drugs, and their bioactive metabolites
